DIADIA0.48%
SPYSPY0.10%
QQQQQQ1.12%
Trending
Top trending tickerSHIBSHIB16.52%
AVAXAVAX6.89%
JASMYJASMY0.05%
PYTHPYTH3.55%
RIGLRIGL0.22%
TAOTAO1.12%
DOGDOG0.17%
ANTHZZXANTHZZX0.62%
PSKYPSKY3.30%
AZNAZN0.59%
Top trending tickerSHIBSHIB16.52%
AVAXAVAX6.89%
JASMYJASMY0.05%
PYTHPYTH3.55%
RIGLRIGL0.22%
TAOTAO1.12%
DOGDOG0.17%
ANTHZZXANTHZZX0.62%
PSKYPSKY3.30%
AZNAZN0.59%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolNKTRnews
Exchange: NASDAQ·Updated 07:34 PM EDT
NKTR logo

NKTRNektar Therapeutics

$70.73
$1.37
(1.97%)
Today
Closed $70.73
$0.805
(1.14%)
After Hours
EarningsAug 6
Mkt Cap$2.39B
Vol836,066.00
News
all
press releases
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, July 24, 2026 SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...
PR Newswire
More News
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis
Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, with a third study set to start in September. Shares rise.
Zacks
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in...
PR Newswire
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema
Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month.
Stocktwits
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, June 26, 2026 SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...
PR Newswire
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock...
Yahoo! Finance: News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, June 3, 2026 SAN FRANCISCO, June 3, 2026 /PRNewswire/ --Nektar Therapeutics (NASDAQ: NKTR) today announced...
PR Newswire
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York PR Newswire SAN FRANCISCO, May 27, 2026 SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar...
PR Newswire
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
Key PointsProsight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter...
Nasdaq News: Markets
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.
Zacks
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.